Aktis Oncology (NASDAQ:AKTS) Coverage Initiated at TD Cowen
TD Cowen started coverage on shares of Aktis Oncology in a report on Tuesday. They issued a "buy" rating for the company...
MarketBeat·2d ago
More News
Aktis Oncology (NASDAQ:AKTS) Now Covered by Bank of America
Bank of America began coverage on Aktis Oncology in a research report on Tuesday. They issued a "buy" rating and a $34.00 price target on the stock...
MarketBeat·2d ago
Aktis Oncology (NASDAQ:AKTS) Now Covered by Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. began coverage on Aktis Oncology in a research note on Tuesday. They issued an "overweight" rating and a $30.00 target price on the stock...
MarketBeat·2d ago
Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Analysts at Leerink Partners
Leerink Partners assumed coverage on shares of Aktis Oncology in a report on Tuesday. They set an "outperform" rating and a $31.00 price objective on the stock...
MarketBeat·2d ago
Aktis Oncology (NASDAQ:AKTS) Shares Down 7.1% - Here's What Happened
Aktis Oncology (NASDAQ:AKTS) Stock Price Down 7.1% - Here's Why...
MarketBeat·13d ago
Aktis Oncology (NASDAQ:AKTS) Stock Price Up 12.3% - Still a Buy?
Aktis Oncology (NASDAQ:AKTS) Trading 12.3% Higher - Here's What Happened...
MarketBeat·13d ago
Aktis Oncology (NASDAQ:AKTS) Reaches New 1-Year Low - Should You Sell?
Aktis Oncology (NASDAQ:AKTS) Sets New 12-Month Low - Should You Sell...